InMed Pharmaceuticals is a global leader in the manufacturing, development and commercialization of rare cannabinoids and proprietary cannabinoid analogs. InMed is a clinical stage company with a robust R&D pipeline with 4 candidates in dermatology, ocular and Alzheimer’s. have unparalleled cannabinoid manufacturing capabilities to serve a spectrum of consumer markets, including pharmaceutical and health and wellness. InMed is in a unique situation as a pharmaceutical company, in the fact that they are also supported by a revenue generating subsidiary, selling rare cannabinoids to the H&W industry with strong revenue growth, including 278% YoY 2023 v 2022. InMed can also claim an extensive proprietary library of novel cannabinoid analogs along with a valuable and growing IP portfolio.
InMed is one of the many featured companies slated to present at The Microcap Conference 2024, set for Jan. 30-Feb. 1 at Caesars Atlantic City Hotel and Casino. This three-day conference presented by DealFlow Events features technical programming designed for microcap investors and a presenting company track for pitching and socializing.
Pipeline:
INM-901 in the treatment of Alzeimhers:
Based on initial preclinical data from in vitro and in vivo studies, the identified cannabinoid analog (INM-901) appears not only to be potentially effective in reducing beta-amyloid plaques (the focus of the current FDA-approved disease-modifying drugs for treating Alzheimer’s), but also seems to have the unique potential to provide neuroprotective effects and enhanced neuronal function.
INM-755 in the treatment of EB
Inmed completed a phase 2 clinical trail in summer last year and believes the Phase II study produced sufficient clinically important chronic itch relief data to support further advancement of the program. The company is currently seeking partnerships to this end.
INM-089 in the treatment of Age-related Macular Degeneration (AMD)
Early preclinical results from an in vivo AMD disease model have demonstrated that INM-089 may have the potential to preserve retinal function, proactively protect retinal cells, and enhance the thickness of the outer nuclear layer of the retina where photoreceptors are situated.
BayMedica has developed efficient and scalable biosynthetic and synthetic chemistry processes to deliver a portfolio of natural cannabinoids including CBC, CBDV, THCV and CBT.
History of the company’s formation
The company in its current structure as a pharmaceutical company has been around since 2014, with Eric Adams taking over in 2016 as CEO. Since 2016 the company has been focused on the pharmaceutical development of rare cannabinoids, researching candidates for a variety of indications. In 2021, the Company acquired a US subsidiary called BayMedica, which is a B2B supplier of rare cannabinoids to the health and wellness market. In 2020, the company uplisted to the Nasdaq from the TSX in Canada.
Key leadership
InMed brings together a depth of cannabinoid expertise, with extensive experience in pharma r&d, cannabinoid/api manufacturing, clinical and regulatory. Together with BayMedica, their management team covers the whole gamut of pharmaceutical development and ingredient manufacturing. Between them, the executive decades worth of pharma experience in top-tier pharma companies.
Looking to the future
- InMed has initiated six-month preclinical studies in behavioral models to further evaluate the potential impact of INM-901 in Alzheimer’s disease with preparations underway for the subsequent phase of advanced preclinical studies.
- Actively seeking partnerships to advance INM-0755 in either EB or itch related indications.
- Advancing INM-089 program towards IND filing / human clinical trials in 2025. The Company is currently engaged in API and drug product formulation work and expects to initiate Investigational New Drug (“IND”)-enabling studies in mid-2024, with the anticipation of filing an IND application with regulatory authorities in calendar 1H 2025.
Anticipated continued revenue growth and market expansion with BayMedica in 2024.
Learn more.
Tickets to the inaugural Microcap Conference 2024 are going fast. Reserve your seat now for three days of unsurpassed networking and technical discussions of the microcap sector with some of the best names in the business – institutional investors, finance-focused law firms, venture and private equity fund managers, deal advisors, PIPE funds, brokerage firms, investor relations professionals, accredited retail investors and many more. The conference schedule is also packed with entertainment and exciting activities set against the backdrop of Atlantic City’s bright lights.
Sponsored content, this is a paid promotion
Comments and opinions presented in DealFlow Events publications such as The Microcap Newsletter are solely those of the analysts, corporate executives, and others quoted. They do not represent the opinions of DealFlow Events and DealFlow Events makes no recommendations on whether to buy, sell or hold shares of any particular stock. Investors are advised to conduct their own research before making an investment decision. Neither DealFlow Events nor any of its affiliates hold any position in the stocks mentioned in The Microcap Newsletter.
